Predictive factors for residual cancer in second transurethral resection for non-muscle-invasive bladder cancer

Masakazu Akitake, Akito Yamaguchi, masaki shiota, Kenjiro Imada, Katsunori Tatsugami, Akira Yokomizo, Seiji Naito, Masatoshi Eto

研究成果: ジャーナルへの寄稿記事

抄録

Background/Aim: The significance of second transurethral resection (TUR), and identification of predictive factors for residual cancer remain unrevealed. This study aimed to find residual cancer and up-staging rates, as well as predictive factors for residual cancer, in patients who undergo second TUR for non-muscle-invasive bladder cancer (NMIBC). Patients and Methods: Patients who underwent second TURs for NMIBC between 2015 and 2017, were included in the study and their clinicopathological characteristics were analyzed for predictors of residual cancer. Results: Among 143 Japanese patients whose tumors were initially diagnosed as high-risk NMIBC, residual cancers detected at second TURs were, Tis: n=22 (15.4%), Ta: n=15 (10.5%) and T1: n=29 (20.3%). No patients showed upstaging from NMIBC to MIBC. The presence of carcinoma-in situ at initial TUR was an independent risk factor for any residual cancer (Tis, Ta and T1), non-flat residual cancer (Ta and T1), and flat residual cancer (Tis). Conclusion: The presence of carcinoma-in situ is suggested to be an independent predictor of residual cancer. This may help guide decisions to perform second TUR.

元の言語英語
ページ(範囲)4325-4328
ページ数4
ジャーナルAnticancer research
39
発行部数8
DOI
出版物ステータス出版済み - 1 1 2019

Fingerprint

Residual Neoplasm
Urinary Bladder Neoplasms
Carcinoma in Situ
Neoplasm Staging

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Predictive factors for residual cancer in second transurethral resection for non-muscle-invasive bladder cancer. / Akitake, Masakazu; Yamaguchi, Akito; shiota, masaki; Imada, Kenjiro; Tatsugami, Katsunori; Yokomizo, Akira; Naito, Seiji; Eto, Masatoshi.

:: Anticancer research, 巻 39, 番号 8, 01.01.2019, p. 4325-4328.

研究成果: ジャーナルへの寄稿記事

@article{0d9d3bb536564baca8997c2646a4b4f6,
title = "Predictive factors for residual cancer in second transurethral resection for non-muscle-invasive bladder cancer",
abstract = "Background/Aim: The significance of second transurethral resection (TUR), and identification of predictive factors for residual cancer remain unrevealed. This study aimed to find residual cancer and up-staging rates, as well as predictive factors for residual cancer, in patients who undergo second TUR for non-muscle-invasive bladder cancer (NMIBC). Patients and Methods: Patients who underwent second TURs for NMIBC between 2015 and 2017, were included in the study and their clinicopathological characteristics were analyzed for predictors of residual cancer. Results: Among 143 Japanese patients whose tumors were initially diagnosed as high-risk NMIBC, residual cancers detected at second TURs were, Tis: n=22 (15.4{\%}), Ta: n=15 (10.5{\%}) and T1: n=29 (20.3{\%}). No patients showed upstaging from NMIBC to MIBC. The presence of carcinoma-in situ at initial TUR was an independent risk factor for any residual cancer (Tis, Ta and T1), non-flat residual cancer (Ta and T1), and flat residual cancer (Tis). Conclusion: The presence of carcinoma-in situ is suggested to be an independent predictor of residual cancer. This may help guide decisions to perform second TUR.",
author = "Masakazu Akitake and Akito Yamaguchi and masaki shiota and Kenjiro Imada and Katsunori Tatsugami and Akira Yokomizo and Seiji Naito and Masatoshi Eto",
year = "2019",
month = "1",
day = "1",
doi = "10.21873/anticanres.13598",
language = "English",
volume = "39",
pages = "4325--4328",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "8",

}

TY - JOUR

T1 - Predictive factors for residual cancer in second transurethral resection for non-muscle-invasive bladder cancer

AU - Akitake, Masakazu

AU - Yamaguchi, Akito

AU - shiota, masaki

AU - Imada, Kenjiro

AU - Tatsugami, Katsunori

AU - Yokomizo, Akira

AU - Naito, Seiji

AU - Eto, Masatoshi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background/Aim: The significance of second transurethral resection (TUR), and identification of predictive factors for residual cancer remain unrevealed. This study aimed to find residual cancer and up-staging rates, as well as predictive factors for residual cancer, in patients who undergo second TUR for non-muscle-invasive bladder cancer (NMIBC). Patients and Methods: Patients who underwent second TURs for NMIBC between 2015 and 2017, were included in the study and their clinicopathological characteristics were analyzed for predictors of residual cancer. Results: Among 143 Japanese patients whose tumors were initially diagnosed as high-risk NMIBC, residual cancers detected at second TURs were, Tis: n=22 (15.4%), Ta: n=15 (10.5%) and T1: n=29 (20.3%). No patients showed upstaging from NMIBC to MIBC. The presence of carcinoma-in situ at initial TUR was an independent risk factor for any residual cancer (Tis, Ta and T1), non-flat residual cancer (Ta and T1), and flat residual cancer (Tis). Conclusion: The presence of carcinoma-in situ is suggested to be an independent predictor of residual cancer. This may help guide decisions to perform second TUR.

AB - Background/Aim: The significance of second transurethral resection (TUR), and identification of predictive factors for residual cancer remain unrevealed. This study aimed to find residual cancer and up-staging rates, as well as predictive factors for residual cancer, in patients who undergo second TUR for non-muscle-invasive bladder cancer (NMIBC). Patients and Methods: Patients who underwent second TURs for NMIBC between 2015 and 2017, were included in the study and their clinicopathological characteristics were analyzed for predictors of residual cancer. Results: Among 143 Japanese patients whose tumors were initially diagnosed as high-risk NMIBC, residual cancers detected at second TURs were, Tis: n=22 (15.4%), Ta: n=15 (10.5%) and T1: n=29 (20.3%). No patients showed upstaging from NMIBC to MIBC. The presence of carcinoma-in situ at initial TUR was an independent risk factor for any residual cancer (Tis, Ta and T1), non-flat residual cancer (Ta and T1), and flat residual cancer (Tis). Conclusion: The presence of carcinoma-in situ is suggested to be an independent predictor of residual cancer. This may help guide decisions to perform second TUR.

UR - http://www.scopus.com/inward/record.url?scp=85070662939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070662939&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13598

DO - 10.21873/anticanres.13598

M3 - Article

VL - 39

SP - 4325

EP - 4328

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 8

ER -